EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?

Lohis Balachandran, Tatt Jhong Haw, Angeline Jia Wen Leong, Amanda J Croft, Dongqing Chen, Conagh Kelly, Aaron L Sverdlov, Doan T M Ngo

Heart, Lung and Circulation · 2024

DOI: 10.1016/j.hlc.2024.01.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Heart, Lung and Circulation, 2024. Verfasst von Lohis Balachandran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Newcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Hunter New England Local Health District, The University of New…. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Antineoplastic Agents, Cell Survival, Cardiotoxicity. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Heart Foundation of Australia, Australian Government Department of Health and Aged Care, NSW Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Increased cancer survivorship represents a remarkable achievement for modern medicine. Unfortunately, cancer treatments have inadvertently contributed to cardiovascular (CV) damage, significantly threatening the health and quality of life of patients living with, through and beyond cancer. Without understanding the mechanisms, including whether the cardiotoxicity is due to the direct or indirect effects on cardiomyocytes, prevention and management of cardiotoxicity can pose challenges in many patients. To date, the cardiotoxicity profiles of most of the chemotherapy drugs are still poorly understood. AIM: To conduct a pilot study to investigate the direct effects of a range of cancer therapies on cardiomyocyte viability. METHODS: Primary human cardiomyocytes (HCM) were cultured and seeded into 96-well culture plates. A total of 35 different Food and Drug Administration-approved anti-cancer drugs were added to the HCM cells with a concentration of 1uM for 72 hours. The viability of HCMs was determined using CellTitre-Glo. The experiments were repeated at least three times for each drug with HCMs of different passages. RESULTS: We identified 15 anti-cancer agents that significantly reduced HCM viability. These drugs were: (1) anthracyclines (daunorubicin [HCM viability, mean %±standard error, 13.7±3.2%], epirubicin [47.6±5.3%]), (2) antimetabolite (azacitidine [67.1±2.4%]), (3) taxanes (paclitaxel [60.2±3.0%]), (4) protein kinase inhibitors (lapatinib [49.8±7.0%], ponatinib [42.4±9.0%], pemigatinib [68.1±2.3%], sorafenib [52.9±10.6%], nilotinib [64.4±4.5%], dasatinib [38.5±3.6%]), (5) proteasome inhibitors (ixazomib citrate [65.4±7.2%]), (6) non-selective histone-deacetylase inhibitor (panobinostat [19.1±4.1%]), poly adenosine diphosphate-ribose polymerase inhibitor (olaparib [68.2±1.7%]) and (7) vinca alkaloids (vincristine [44.6±7.4%], vinblastine [31.2±3.9%]). CONCLUSIONS: In total, 15 of the 35 commercially available anti-cancer drugs have direct cardiotoxic effects on HCM. Some of those, have not been associated with clinical cardiotoxicity, while others, known to be cardiotoxic do not appear to mediate it via direct effects on cardiomyocytes. More detailed investigations of the effects of cancer therapies on various cardiovascular cells should be performed to comprehensively determine the mechanisms of cardiotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacAntineoplastic AgentsCell SurvivalCardiotoxicityHumansNeoplasmsCells, CulturedPilot ProjectsFemale

Stichwörter der Autor:innen

Cardio-oncologyCardioprotectiveCardiotoxicityCell viabilityChemotherapyHuman cardiomyocytes

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Newcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Hunter New England Local Health District, The University of Newcastle and Calvary Mater Newcastle, Newcastle, NSW, Australia.
  • Newcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Hunter New England Local Health District, The University of Newcastle and Calvary Mater Newcastle, Newcastle, NSW, Australia. Electro…

Förderung

  • National Heart Foundation of Australia
  • Australian Government Department of Health and Aged Care
  • NSW Health

Zitieren

APA

Balachandran, L., Haw, T. J., Leong, A. J. W., Croft, A. J., Chen, D., Kelly, C., Sverdlov, A. L., & Ngo, D. T. M. (2024). Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?. Heart, Lung and Circulation. https://doi.org/10.1016/j.hlc.2024.01.013

Vancouver

Balachandran L, Haw TJ, Leong AJW, Croft AJ, Chen D, Kelly C, et al. Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?. Heart, Lung and Circulation. 2024. doi:10.1016/j.hlc.2024.01.013

BibTeX
@article{Balachandran2024,
  author = {Balachandran, Lohis and Haw, Tatt Jhong and Leong, Angeline Jia Wen and Croft, Amanda J and Chen, Dongqing and Kelly, Conagh and Sverdlov, Aaron L and Ngo, Doan T M},
  title = {Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?},
  journal = {Heart, Lung and Circulation},
  year = {2024},
  doi = {10.1016/j.hlc.2024.01.013}
}
Kostenlos starten →